

RECEIVED


APR 15 2002

TECH CENTER 1600/2900

#50
Rec'd
4/17/02
PATENT

Attorney Docket No. 3495.0004-04

Customer Number: 22,852



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Luc MONTAGNIER et al.

Serial No.: 08/067,148

Filed: May 26, 1993

)
)
) Group Art Unit: 1648
)
) Examiner: J. PARKIN
)
)

For: ANTIBODIES WHICH BIND WITH PROTEINS OF HUMAN
IMMUNODEFICIENCY VIRUS TYPE 1 (HIV-1), AND IMMUNE COMPLEXES
COMPRISING PROTEINS OF HIV-1 (As Amended)

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

RESPONSE TO PAPER NO. 47

In response to the Office Action dated October 10, 2001 (Paper No. 47), the period for response to which has been extended by submission of a petition for a three-month extension of time and fee concurrently herewith, applicants submit the following remarks.

REMARKS

Claims 29-31 and 37-44 were rejected under 35 U.S.C. § 112, first paragraph, for allegedly containing subject matter that was not described in the specification in such a way as to reasonably convey to the skilled artisan that the inventors had possession of the claimed invention at the time the application was filed. Applicants traverse the rejection.

The specification teaches that the invention relates to biological reagents that can be formed using HIV-1 extracts containing the p25 protein or using purified p25 protein, particularly for the production of antibodies in animals or monoclonal antibodies. (Specification

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com